Connection
Michael Graner to Cancer Vaccines
This is a "connection" page, showing publications Michael Graner has written about Cancer Vaccines.
|
|
Connection Strength |
|
 |
|
 |
|
2.090 |
|
|
|
-
Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia. 2013 Aug; 29(5):390-8.
Score: 0.393
-
Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure. Int J Hyperthermia. 2013 Sep; 29(6):520-7.
Score: 0.392
-
Graner MW, Romanoski A, Katsanis E. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia. 2013 Aug; 29(5):380-9.
Score: 0.392
-
Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother. 2003 Apr; 52(4):226-34.
Score: 0.192
-
Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother. 2000 Nov; 49(9):476-84.
Score: 0.164
-
Graner MW. Extracellular vesicles in cancer immune responses: roles of purinergic receptors. Semin Immunopathol. 2018 09; 40(5):465-475.
Score: 0.141
-
Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J. 2007 Jul; 21(9):2173-84.
Score: 0.063
-
Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant. 2006 Mar; 12(3):275-83.
Score: 0.059
-
Ramanathapuram LV, Hahn T, Graner MW, Katsanis E, Akporiaye ET. Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunol Immunother. 2006 Feb; 55(2):166-77.
Score: 0.057
-
Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother. 2006 Mar; 55(3):329-38.
Score: 0.056
-
Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood. 2005 Mar 01; 105(5):2016-22.
Score: 0.054
-
Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer. 2004 Jun 10; 110(2):251-9.
Score: 0.053
-
Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res. 2000 Mar; 6(3):909-15.
Score: 0.039
-
Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Int J Hyperthermia. 2008 Dec; 24(8):623-37.
Score: 0.018
-
Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May; 8(5):717-32.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|